Pelvic Lymph Node Dissection (PLND): A Comprehensive Clinical Guide

Pelvic Lymph Node Dissection (PLND), also frequently referred to as pelvic lymphadenectomy, is a foundational surgical procedure in oncological urology and gynecology. It involves the systematic surgical removal of lymph nodes from the pelvic basin, a critical diagnostic and therapeutic step in the staging and management of malignancies such as prostate, bladder, cervical, and endometrial cancers.

As an expert clinical procedure, PLND serves a dual purpose: it provides essential pathological data for precise cancer staging (pathological staging) and acts as a therapeutic intervention by removing potentially metastatic disease, thereby improving long-term survival outcomes.

1. Deep-Dive: Technical Specifications and Mechanisms

The pelvic lymphatic system is a complex network of vessels and nodes that drain the pelvic viscera. PLND is categorized based on the anatomical extent of the dissection.

Anatomical Boundaries

The dissection typically targets three primary nodal groups:
1. External Iliac Nodes: Located along the external iliac vessels.
2. Internal Iliac (Hypogastric) Nodes: Located along the internal iliac vessels.
3. Obturator Nodes: Situated within the obturator fossa, bound by the obturator nerve superiorly and the pelvic floor inferiorly.

Classification of Dissection

The mechanism of the procedure relies on meticulous sharp and blunt dissection, often facilitated by robotic-assisted (RARP) or laparoscopic platforms, which provide high-definition visualization of the vascular architecture (iliac vessels) and the delicate nerves (obturator nerve) traversing the surgical field.

2. Extensive Clinical Indications and Usage

PLND is not performed in isolation but is almost exclusively performed in conjunction with the primary resection of the tumor (e.g., radical prostatectomy or radical cystectomy).

Primary Indications

• Prostate Cancer: Indicated for patients with intermediate to high-risk disease (based on Gleason score, PSA levels, and clinical stage). The Briganti Nomogram is frequently used to calculate the probability of nodal involvement to determine the necessity of PLND.
• Bladder Cancer: Essential in radical cystectomy. The extent of PLND is a significant prognostic factor for survival in muscle-invasive bladder cancer.
• Gynecological Malignancies: Routine for staging of endometrial and cervical cancers to guide adjuvant therapy (chemotherapy or radiation).
• Penile and Urethral Cancers: In specific cases, to assess metastatic spread.

Contraindications

• Systemic Metastasis: If distant metastasis (e.g., bone or lung) is confirmed, the morbidity of a radical PLND may outweigh the benefit, unless performed for palliative debulking.
• Severe Comorbidities: Patients with high anesthetic risk (ASA IV/V) or severe coagulopathy may be unsuitable candidates.
• Prior Pelvic Radiation: Previous radiation can create dense fibrosis, increasing the risk of vascular injury and nerve damage.

3. Patient Pre-operative Preparation

Success in PLND is heavily predicated on rigorous pre-operative planning.

• Imaging: Cross-sectional imaging (CT, MRI, or PET/CT) is mandatory to identify bulky, suspicious nodes that may require specialized surgical approaches.
• Thromboprophylaxis: Due to the risk of venous thromboembolism (VTE) in pelvic surgery, mechanical (SCDs) and chemical (LMWH) prophylaxis is standard.
• Bowel Preparation: While not always required for robotic procedures, bowel clearance may be utilized to improve visualization in the pelvic cavity.
• Informed Consent: Patients must be educated on the specific risks of lymphedema, vascular injury, and the potential for prolonged drainage.

4. The Surgical Procedure: Step-by-Step

Modern PLND is predominantly performed via a minimally invasive approach.

Step 1: Exposure and Development of Spaces

The surgeon enters the retroperitoneum, identifying the ureter as the primary landmark. The paravesical and pararectal spaces are developed to expose the pelvic sidewall.

Step 2: Identification of Vascular Landmarks

The bifurcation of the common iliac artery is identified. The external iliac artery and vein are skeletonized by retracting them medially and laterally.

Step 3: Nodal Resection

• External Iliac: Lymphatic tissue is dissected off the external iliac vein.
• Obturator Fossa: The most critical step. The obturator nerve is identified and protected. Lymphatic tissue is removed from the obturator fossa, ensuring the obturator vein is controlled.
• Internal Iliac: The nodal package along the internal iliac artery is cleared, ensuring all fibro-fatty tissue is removed to the level of the pelvic floor.

Step 4: Hemostasis and Drainage

After confirming the integrity of the iliac vessels and the obturator nerve, the field is irrigated. A closed-suction drain is often placed if the dissection is extensive to mitigate the risk of lymphocele formation.

5. Post-operative Recovery Protocol

Post-operative care focuses on early mobilization and monitoring for complications.

1. Immediate Post-op: Monitoring of urine output and drain fluid volume/color.
2. Mobilization: Patients are encouraged to ambulate within 24 hours to reduce the risk of deep vein thrombosis (DVT).
3. Drain Management: Drains are typically removed when output is minimal (usually <50-100ml per day) and serous in nature.
4. Pathological Review: The "node count" is a quality metric. Surgeons aim for a minimum number of nodes (e.g., >10-15) to ensure an adequate oncological evaluation.

6. Risks, Complications, and Management

Despite its necessity, PLND is associated with specific morbidity.

• Lymphocele: The most common complication. A collection of lymphatic fluid in the pelvis. Managed via aspiration or percutaneous drainage if symptomatic (pain, infection, or venous compression).
• Vascular Injury: Injury to the external iliac vein is the most feared intraoperative complication, requiring immediate vascular repair.
• Nerve Injury: Temporary or permanent injury to the obturator nerve can lead to adductor muscle weakness or sensory loss on the medial thigh.
• Lymphedema: Chronic swelling of the lower extremities, occurring in 5-10% of patients following extensive dissection.
• Infection: Pelvic abscesses can occur, particularly if the bowel is inadvertently compromised.

7. Massive FAQ Section

Q1: What is the "node count" and why does it matter?

A: The node count is the number of lymph nodes removed. A higher count generally correlates with a more accurate cancer staging and improved survival, as it reduces the likelihood of leaving behind micrometastatic disease.

Q2: Is PLND always necessary for prostate cancer?

A: No. It is determined by risk stratification models (like Briganti). Low-risk patients rarely require PLND, while high-risk patients almost always require an extended dissection.

Q3: What is a lymphocele?

A: It is a pocket of stagnant lymphatic fluid that develops in the space where the lymph nodes were removed. Most are asymptomatic and resolve on their own.

Q4: How long does the procedure take?

A: When performed with a prostatectomy or cystectomy, the lymph node dissection typically adds 45–90 minutes to the total operative time, depending on the extent of the dissection.

Q5: Will I have permanent swelling in my legs?

A: Lymphedema is a known risk, but the incidence of severe, chronic lymphedema is relatively low (under 10%) with modern surgical techniques.

Q6: Can PLND be performed if I have had prior pelvic surgery?

A: Yes, but it is technically more challenging due to scar tissue. Advanced laparoscopic or robotic imaging helps navigate these difficult planes.

Q7: What are the symptoms of a pelvic lymphocele?

A: Symptoms include lower abdominal pain, a feeling of fullness, swelling of the legs or scrotum, and in severe cases, signs of infection like fever or chills.

Q8: How is the obturator nerve protected?

A: The nerve is visualized early in the dissection. The surgeon uses gentle retraction and avoids the use of energy (cautery) in close proximity to the nerve to prevent thermal injury.

Q9: Does PLND affect sexual function?

A: The PLND itself does not typically impact sexual function; however, the primary surgery performed alongside it (e.g., radical prostatectomy) often does involve nerve-sparing techniques that aim to preserve potency.

Q10: What is the difference between diagnostic and therapeutic PLND?

A: Diagnostic PLND is performed to determine the stage of the cancer (is it limited to the prostate or has it spread?). Therapeutic PLND involves removing known or suspected metastatic disease to reduce the total tumor burden in the body.

8. Alternative Treatments

While PLND remains the gold standard for staging, the field is evolving:

1. Sentinel Lymph Node Biopsy (SLNB): Using fluorescent dyes (like Indocyanine Green - ICG), surgeons can identify the specific node that drains the tumor. This allows for a more targeted "sampling" rather than a full dissection, potentially reducing the risk of lymphedema.
2. Molecular Imaging: Advanced PET tracers (like PSMA-PET for prostate cancer) are becoming so sensitive that they can detect nodal metastasis before surgery, potentially allowing for "spot-dissection" of specific nodes rather than a prophylactic template dissection.
3. Radiotherapy: In some cases, external beam radiation therapy to the pelvic lymph nodes is used as an alternative to surgical removal, particularly in patients who are not surgical candidates.

Conclusion

Pelvic Lymph Node Dissection remains a cornerstone of modern oncological surgery. While the procedure carries inherent risks, the ability to accurately stage malignancy and provide a therapeutic benefit makes it an indispensable tool for the surgical oncologist. Through meticulous anatomical knowledge, the use of advanced robotic platforms, and a focus on minimizing morbidity, surgeons continue to refine this procedure to offer the best possible oncological outcomes for their patients.